Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
RET-IRD-04
RET-IRD-04
Efficacy and safety of QLT091001 in subjects with Inherited Retinal Disease (IRD) caused by gene mutations.
Type: Interventional
Status of the trial: Unknown
Orphan Drug Recognition: No
Inclusion
- Opening Date: 2017-12-12
- Closing Date: 2018-12-12
Criteria
Inclusion: Genotype-confirmed Leber congenital amaurosis attributable
Exclusion: Prior gene therapy
Children: No
Adults: No
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
